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Summary. With advancing age, the likelihood of B- 
amyloid deposition in the cerebral vasculature increases, 
particularly in individuals with Alzheimer's disease. The 
B-amyloid typically accumulates in the basal lamina of 
the arteriolar tunica media, and frequently extends into 
the adjacent neuropil. Cerebrovascular B-amyloid 
increases the risk of hemorrhagic stroke, and may also 
play a role in the pathogenesis of AD. Genetic variations 
have been identified that are causative or risk factors for 
cerebrovascular B-amyloid, including particular 
mutations in the genes for 0-amyloid precursor protein, 
presenilins 1 and 2, and possibly cystatin C, as well as 
polymorphisms in apolipoprotein E. Cerebrovascular 
amyloidosis is now being studied in a variety of in vitro 
and in vivo models, including cultured vascular smooth 
muscle cells, transgenic mice, and aged animals such as 
nonhuman primates. Methods for delivering agents 
selectively to vascular amyloid in living subjects are 
now being developed, and these techniques are paving 
the way to the development of diagnostic tools and 
therapies for cerebrovascular amyloidosis. 
Key words: Alzheimer's disease, B-amyloid, Cerebral 
amyloid angiopathy, Transgenic mice, Primate, Cystatin 
C, Stroke 
Introduction 
In cerebrovascular amyloidosis (CVA), amyloid is 
deposited in the walls of cerebral and meningeal blood 
vessels. Because it renders the vascular wall more 
susceptible to rupture, CVA increases the risk of 
intracerebral bleeding, and may be responsible for 15- 
20% of hemorrhagic stroke in the elderly (Vinters, 1987; 
Kase, 1994). CVA may also promote intracerebral 
hemorrhage in patients treated with thrombolytic agents, 
such as recombinant tissue type plasminogen activator 
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(Sloan et al., 1995). Although several different proteins 
can form the definitive B-pleated sheets of amyloid in 
the brain vasculature, the most common type of cerebro- 
vascular amyloid derives from the B-amyloid peptide 
(AB), which also forms the cores of senile plaques in 
Alzheimer's disease (Wong et al., 1985; Van Duinen et 
al., 1987; Castaiio and Frangione, 1988; Joachim et al., 
1988; Prelli et al., 1988a). AB is a peptide of 39-43 
amino acids that is derived from the B-amyloid precursor 
protein (BPP; Haass and Selkoe, 1993; Schenk et al., 
1995). The form of AB in vascular B-amyloid differs 
somewhat from that in the brain parenchyma (Prelli et 
al., 1988a,b; Roher et al., 1993; Castaiio et al., 1996), 
and also may be younger than plaque amyloid in the 
Alzheimer brain (Roher et al., 1993). There is evidence 
that vascular abnormalities may contribute to the genesis 
of senile plaques (Miyakawa et al., 1974, 1982; Glenner, 
1979), a hypothesis that remains controversial (Kawai et 
al., 1990, 1992). While various conditions can promote 
CVA (Vinters, 1992), the most prominent risk factors for 
the disorder are increasing age (Tomonaga, 1981; 
Vinters and Gilbert, 1983; Esiri and Wilcock, 1986), 
Alzheimer's disease (Mandybur, 1975;  Esiri and 
Wilcock, 1986; Yamada et al., 1987; Vinters, 1992; Ellis 
et al., 1996; Premkumar et al., 1996), and genetic 
influences (Ghiso et al., 1986; Luyendijk et al., 1986; 
Castaiio and Frangione, 1988; Levy et al., 1989, 1990; 
Van Broeckhoven et al., 1990; Haan et al., 1991; 
Hendriks et al., 1992;  Graffagnino et al., 1995;  
Greenberg et al., 1995; Petersen et al., 1995; Wattendorff 
et al., 1995; Bornebroek et al., 1996; Olafsson et al., 
1996; Premkumar et al., 1996; Vidal et al., 1996; Warzok 
et al., 1998). In Alzheimer's disease, there is  a 
relationship between CVA and the degree of cerebral 
arteriosclerosis (Ellis et al., 1996). 
Genetic influences on CVA 
Genetics present a fortuitous window on the 
pathobiology of CVA. Older persons with one or two 
apolipoprotein E - ~ 4  alleles,  in addition to being 
predisposed to Alzheimer's disease, tend also to have a 
greater vascular B-amyloid load (Greenberg et al., 1995; 










